Huawei plans for more AI pharma tie-ups, says healthcare president

(Catch all the Technology News News, and Latest News Updates on The Economic Times.)

SynopsisThe move highlights Huawei's ambitions to gain a foothold in the fast-growing AI drug discovery market, where pharmaceutical ‌companies are ⁠investing in ⁠modelling tools and automated laboratories to shorten development timelines and improve ​efficiency.

ReutersChinese technology conglomerate Huawei plans to expand ​its AI cooperation with ​local pharmaceutical firms into drug development and clinical ​practice, a senior executive said.

The move highlights Huawei's ambitions to gain a foothold in the fast-growing AI drug discovery market, where pharmaceutical ‌companies are ⁠investing in ⁠modelling tools and automated laboratories to shorten development timelines and improve ​efficiency.

"As we further deepen our research into AI in the medical field, ​we'll have more collaboration and results emerging with pharmaceutical companies from drug manufacturing to clinical to final implementation," William ​Zhang, president of Huawei's healthcare business ⁠unit, told ‌Reuters on Wednesday.

He said that Huawei had ​some existing ​collaborations in the area of clinical practice in ⁠hospitals and was exploring more opportunities, without ​further elaboration.

The projects now are mainly with domestic ​drugmakers, he said.

US chip giant Nvidia has struck AI-related partnerships with drugmakers such as Eli Lilly and Novo Nordisk, as technology companies seek to capitalise on growing demand for AI-powered drug research.

Huawei offers tools for screening potentially ‌viable drug compounds, alongside its Ascend and Kunpeng chips.

In May, Huawei said one project involving state-owned Guangzhou Pharmaceutical Holdings was the ⁠industry's first production validation of independently developed AI drug research models that were adapted to its Ascend and Kunpeng technologies.

Industry forecasts ​suggest that the use of machine learning to optimize target discovery, design molecules and streamline clinical trial planning could halve early-stage development timelines and costs within the next three to five years, Reuters has previously reported.

Read more news onHuawei AI healthcare partnershipsAI drug developmentpharmaceutical collaborationsclinical trials AIdrug discovery technologyAscend Kunpeng chipsGuangzhou Pharmaceutical Holdings

(Catch all the Technology News News, and Latest News Updates on The Economic Times.)

Elevate your knowledge and leadership skills at a cost cheaper than your daily tea.

As IndiGo, Air India scramble for pilots, fresh headwinds hit hardWhen a CFO resigns, is ‘personal reasons’ explanation enough?FCNR (B) scheme garners USD65 bn, but why isn't the rupee gaining?ET Prime special: Bigger, Better or Both? Understanding business to figure out the mystery: Power Grid Corp – Part 1US bond yield: Will it become a new pain point?Bigger or Better: BEL’s biggest shareholder is also its biggest customer – and its rule-maker. Final partTrain station to rocket propellants, a Nagpur firm’s INR21k-cr journeyThe Nifty doesn't predict India. It records itET Prime special series: Bigger or Better? Bharat Electronics’ 2013 to 2026 journey – Part 2ET Prime special series: Bigger or Better? Bharat Electronics’ 2013 to 2026 journey – Part 1